Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020.

Elizabeth LazaridouGeorgia KourlabaStylianos RavanidisGeorge GounelasGaryfallia StefanouAnastasios TsolakidisKonstantinos MathioudakisZoe Apalla

Published in: Clinical and experimental dermatology (2024)

Our findings confirm previous reports regarding the importance of efficient 1st line biologics and the vulnerability of patients to co-existent PsA. The utilitzation of antibodies against interleukins confer to high drug survival rates. These results will assist clinical management of psoriasis patients in Greece.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
emergency department
climate change
free survival